Incendia Therapeutics to Present at 35th Annual Piper Sandler Healthcare Conference

2023-11-22

临床1期ASCO会议

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Incendia Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that Chief Executive Officer, Wendye R. Robbins, M.D., will present a corporate overview at the 35th Annual Piper Sandler Healthcare Conference on Thursday, November 30, 2023 at 2:50 pm ET. About Incendia Therapeutics Incendia Therapeutics is discovering and developing a novel class of experimental therapeutics that reprogram the tumor microenvironment (TME). Incendia’s platform is based on rigorous, groundbreaking research involving tumor bioinformatics, deep genetic sequencing, and extensive preclinical testing. The Company’s most advanced experimental molecule, PRTH-101, recently initiated a Phase 1b trial for the treatment of patients with advanced solid tumors of epithelial cell origin. For more information visit incendia.com and LinkedIn.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构